|
Gastric Inhibitory Polypeptide
|
D06.472.699.275 |
|
|
Adverse Drug Reaction Reporting Systems
|
N02.421.668.320.120 |
|
|
Neutral Glycosphingolipids
|
D10.390.470.675 |
|
|
Vitamin K 2
|
D02.455.426.559.847.638.721.374.844 |
|
|
Vitamin K
|
D02.455.426.559.847.638.721.374 |
|
|
Cambodia
|
Z01.252.145.182 |
|
|
Stigmasterol
|
D04.210.500.247.222.222.347.833 |
|
|
Cholestadienols
|
D04.210.500.247.222.222.347 |
|
|
Flurogestone Acetate
|
D04.210.500.745.745.654.485 |
|
|
Flowering Tops
|
A18.024.249 |
|
|
Plant Components, Aerial
|
A18.024 |
|
|
C-Reactive Protein
|
D12.776.124.050.120 |
|
|
Edaravone
|
D03.383.129.539.850.088.500 |
|
|
Antipyrine
|
D03.383.129.539.850.088 |
|
|
Sildenafil Citrate
|
D02.065.884.675 |
|
|
Quillaja
|
B01.650.940.800.575.912.250.859.937.500.724 |
|
|
Encephalitis, California
|
C01.925.782.147.340 |
|
|
Bunyaviridae Infections
|
C01.925.782.147 |
|
|
Diabetes Complications
|
C19.246.099 |
|
|
National Institute of Arthritis and Musculoskeletal and Skin Diseases (U.S.)
|
D054580 |
[Component of the NATIONAL INSTITUTES OF HEALTH. It supports research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases; the training of basic and clinical scientists to carry out this research; and the dissemination of information on research progress. It was established in 1986.
] |
